275 related articles for article (PubMed ID: 23582272)
1. Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3438-42. PubMed ID: 23582272
[TBL] [Abstract][Full Text] [Related]
2. Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: optimization studies and demonstration of in vivo efficacy.
Plummer MS; Cornicelli J; Roark H; Skalitzky DJ; Stankovic CJ; Bove S; Pandit J; Goodman A; Hicks J; Shahripour A; Beidler D; Lu XK; Sanchez B; Whitehead C; Sarver R; Braden T; Gowan R; Shen XQ; Welch K; Ogden A; Sadagopan N; Baum H; Miller H; Banotai C; Spessard C; Lightle S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3443-7. PubMed ID: 23597790
[TBL] [Abstract][Full Text] [Related]
3. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition.
Abusnina A; Keravis T; Zhou Q; Justiniano H; Lobstein A; Lugnier C
Thromb Haemost; 2015 Feb; 113(2):319-28. PubMed ID: 25230992
[TBL] [Abstract][Full Text] [Related]
4. Discovery of triazines as potent, selective and orally active PDE4 inhibitors.
Gewald R; Grunwald C; Egerland U
Bioorg Med Chem Lett; 2013 Aug; 23(15):4308-14. PubMed ID: 23806553
[TBL] [Abstract][Full Text] [Related]
5. Thiophene inhibitors of PDE4: crystal structures show a second binding mode at the catalytic domain of PDE4D2.
Nankervis JL; Feil SC; Hancock NC; Zheng Z; Ng HL; Morton CJ; Holien JK; Ho PW; Frazzetto MM; Jennings IG; Manallack DT; Martin TJ; Thompson PE; Parker MW
Bioorg Med Chem Lett; 2011 Dec; 21(23):7089-93. PubMed ID: 22030030
[TBL] [Abstract][Full Text] [Related]
6. The identification of a novel lead class for phosphodiesterase 2 inhibition by fragment-based drug design.
Forster AB; Abeywickrema P; Bunda J; Cox CD; Cabalu TD; Egbertson M; Fay J; Getty K; Hall D; Kornienko M; Lu J; Parthasarathy G; Reid J; Sharma S; Shipe WD; Smith SM; Soisson S; Stachel SJ; Su HP; Wang D; Berger R
Bioorg Med Chem Lett; 2017 Dec; 27(23):5167-5171. PubMed ID: 29113762
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a new series of [1,2,4]triazolo[4,3-a]quinoxalines as dual phosphodiesterase 2/phosphodiesterase 10 (PDE2/PDE10) inhibitors.
Andrés JI; Buijnsters P; De Angelis M; Langlois X; Rombouts F; Trabanco AA; Vanhoof G
Bioorg Med Chem Lett; 2013 Feb; 23(3):785-90. PubMed ID: 23260348
[TBL] [Abstract][Full Text] [Related]
8. PDE2 inhibition: potential for the treatment of cognitive disorders.
Gomez L; Breitenbucher JG
Bioorg Med Chem Lett; 2013 Dec; 23(24):6522-7. PubMed ID: 24189054
[TBL] [Abstract][Full Text] [Related]
9. Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.
Iffland A; Kohls D; Low S; Luan J; Zhang Y; Kothe M; Cao Q; Kamath AV; Ding YH; Ellenberger T
Biochemistry; 2005 Jun; 44(23):8312-25. PubMed ID: 15938621
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel N-1 substituted pyrazolopyrimidinones as potent, selective PDE2 inhibitors.
Morriello GJ; Dwyer MP; Chen Y; Ginetti AT; Xu S; Lu J; Abeywickrema P; Wang D; Crespo A; Cabalu TD; Wilson JE; Stachel SJ; Paone DV; Sinz C
Bioorg Med Chem Lett; 2021 Jul; 44():128082. PubMed ID: 33991626
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of phosphodiesterases PDE2, PDE3, and PDE4 do not increase the sinoatrial tachycardia of noradrenaline and prostaglandin PGE₁ in mice.
Galindo-Tovar A; Vargas ML; Kaumann AJ
Naunyn Schmiedebergs Arch Pharmacol; 2016 Feb; 389(2):177-86. PubMed ID: 26531832
[TBL] [Abstract][Full Text] [Related]
12. Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration.
Woodrow MD; Ballantine SP; Barker MD; Clarke BJ; Dawson J; Dean TW; Delves CJ; Evans B; Gough SL; Guntrip SB; Holman S; Holmes DS; Kranz M; Lindvaal MK; Lucas FS; Neu M; Ranshaw LE; Solanke YE; Somers DO; Ward P; Wiseman JO
Bioorg Med Chem Lett; 2009 Sep; 19(17):5261-5. PubMed ID: 19656678
[TBL] [Abstract][Full Text] [Related]
13. X-ray crystal structure of phosphodiesterase 2 in complex with a highly selective, nanomolar inhibitor reveals a binding-induced pocket important for selectivity.
Zhu J; Yang Q; Dai D; Huang Q
J Am Chem Soc; 2013 Aug; 135(32):11708-11. PubMed ID: 23899287
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel purine nucleoside derivatives as phosphodiesterase 2 (PDE2) inhibitors: Structure-based virtual screening, optimization and biological evaluation.
Qiu X; Huang Y; Wu D; Mao F; Zhu J; Yan W; Luo HB; Li J
Bioorg Med Chem; 2018 Jan; 26(1):119-133. PubMed ID: 29174506
[TBL] [Abstract][Full Text] [Related]
15. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors.
Wang H; Peng MS; Chen Y; Geng J; Robinson H; Houslay MD; Cai J; Ke H
Biochem J; 2007 Dec; 408(2):193-201. PubMed ID: 17727341
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes.
Paes D; Xie K; Wheeler DG; Zook D; Prickaerts J; Peters M
Neuropharmacology; 2021 Feb; 184():108414. PubMed ID: 33249120
[TBL] [Abstract][Full Text] [Related]
18. Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.
Goto T; Shiina A; Yoshino T; Mizukami K; Hirahara K; Suzuki O; Sogawa Y; Takahashi T; Mikkaichi T; Nakao N; Takahashi M; Hasegawa M; Sasaki S
Bioorg Med Chem Lett; 2013 Jun; 23(11):3325-8. PubMed ID: 23602400
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 1,4-dihydropyridine-based PDE4 inhibitors.
Poondra RR; Nallamelli RV; Meda CL; Srinivas BN; Grover A; Muttabathula J; Voleti SR; Sridhar B; Pal M; Parsa KV
Bioorg Med Chem Lett; 2013 Feb; 23(4):1104-9. PubMed ID: 23294698
[TBL] [Abstract][Full Text] [Related]
20. Distinct patterns of constitutive phosphodiesterase activity in mouse sinoatrial node and atrial myocardium.
Hua R; Adamczyk A; Robbins C; Ray G; Rose RA
PLoS One; 2012; 7(10):e47652. PubMed ID: 23077656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
